Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Blackpink's solo journeys: Complementary paths, not competition
-
5
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
6
Korean Air offers special flights for mileage users
-
7
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
10
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
[THE INVESTOR] Cell therapy developer Green Cross Cell and biotechnology firm ToolGen on Aug. 22 signed a memorandum of understanding on collaborating in developing immune therapy for cancer.
The two companies plan to apply ToolGen’s DNA scissor technology to Green Cross Cell’s anti-cancer immune therapy.
The companies hope to amplify T-cells’ ability to attack cancer cells.
By Choi He-suk (cheesuk@heraldcorp.com)
The two companies plan to apply ToolGen’s DNA scissor technology to Green Cross Cell’s anti-cancer immune therapy.
The companies hope to amplify T-cells’ ability to attack cancer cells.
By Choi He-suk (cheesuk@heraldcorp.com)
